PDS Biotechnology (PDSB) Financials

PDS Biotechnology logo
$0.78 -0.03 (-4.02%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.78 +0.01 (+0.72%)
As of 11/20/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for PDS Biotechnology

Annual Income Statements for PDS Biotechnology

This table shows PDS Biotechnology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-32 -39 -51 -3.84 -7.00 -15 -17 -41 -43 -38 -34
Consolidated Net Income / (Loss)
-28 -39 -51 -3.84 -7.00 -15 -17 -41 -43 -38 -34
Net Income / (Loss) Continuing Operations
-28 -39 -51 -3.84 -7.00 -15 -17 -41 -43 -38 -34
Total Pre-Tax Income
-29 -41 -53 -3.84 -7.38 -15 -21 -42 -44 -38 -36
Total Operating Income
-26 -40 -52 -3.65 -21 -15 -21 -42 -43 -36 -32
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
26 40 52 3.65 21 15 21 42 43 36 32
Selling, General & Admin Expense
8.66 15 18 2.79 11 6.98 10 12 15 14 13
Research & Development Expense
18 25 34 0.83 6.10 7.92 11 29 28 23 19
Total Other Income / (Expense), net
-2.69 -1.15 -1.48 -0.19 14 0.06 0.01 -0.38 -1.30 -2.16 -4.12
Interest Expense
0.82 1.20 2.18 0.19 0.03 - 0.00 1.32 4.21 4.67 5.34
Interest & Investment Income
0.01 0.21 0.70 0.00 0.35 0.06 0.01 0.94 2.90 2.51 1.22
Income Tax Expense
-1.11 -1.85 -2.59 0.00 -0.38 0.00 -4.52 -1.20 -1.41 -0.87 -1.17
Basic Earnings per Share
- - - $1.15 ($1.44) ($0.89) ($0.66) ($1.43) ($1.39) ($1.03) ($0.74)
Weighted Average Basic Shares Outstanding
8.09M 28.86M 30.39M 3.34M 4.87M 16.75M 25.60M 28.60M 30.95M 36.45M 46.38M
Diluted Earnings per Share
- - - $1.15 ($1.44) ($0.89) ($0.66) ($1.43) ($1.39) ($1.03) ($0.74)
Weighted Average Diluted Shares Outstanding
8.09M 28.86M 30.39M 3.34M 4.87M 16.75M 25.60M 28.60M 30.95M 36.45M 46.38M
Weighted Average Basic & Diluted Shares Outstanding
8.09M 28.86M 30.39M 3.34M 4.87M 16.75M 28.45M 30.72M 36.68M 45.40M 55.82M

Quarterly Income Statements for PDS Biotechnology

This table shows PDS Biotechnology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-11 -8.33 -11 -7.95 -8.49 -9.43 -9.01 -7.56 -7.35 -9.75 -7.62
Consolidated Net Income / (Loss)
-11 -8.33 -11 -7.95 -8.49 -9.43 -9.01 -7.56 -7.35 -9.75 -7.62
Net Income / (Loss) Continuing Operations
-11 -8.33 -11 -7.95 -8.49 -9.43 -9.01 -7.56 -7.35 -9.75 -7.62
Total Pre-Tax Income
-11 -9.20 -11 -7.95 -9.66 -9.43 -9.01 -7.56 -7.35 -9.75 -7.62
Total Operating Income
-10 -8.68 -10 -7.36 -9.11 -7.62 -8.14 -6.67 -6.52 -6.50 -5.90
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
10 8.68 10 7.36 9.11 7.62 8.14 6.67 6.52 6.50 5.90
Selling, General & Admin Expense
3.39 4.16 3.37 2.83 3.27 3.41 3.56 2.27 3.06 3.23 3.84
Research & Development Expense
6.70 4.53 6.80 4.53 5.83 4.21 4.58 4.41 3.46 3.27 2.05
Total Other Income / (Expense), net
-0.51 -0.51 -0.55 -0.59 -0.55 -1.81 -0.87 -0.89 -0.83 -3.25 -1.72
Interest Expense
1.17 1.19 1.21 1.10 0.93 2.14 1.15 1.11 1.01 3.38 1.77
Interest & Investment Income
0.67 0.68 0.67 0.50 0.38 0.33 0.28 0.22 0.19 0.13 0.04
Income Tax Expense
0.00 -0.87 0.00 - -1.17 0.00 0.00 - 0.00 0.00 0.00
Basic Earnings per Share
($0.30) ($0.23) ($0.29) ($0.21) ($0.21) ($0.21) ($0.19) ($0.13) ($0.13) ($0.18) ($0.11)
Weighted Average Basic Shares Outstanding
34.82M 36.69M 36.81M 36.45M 40.52M 45.90M 46.87M 46.38M 55.50M 55.66M 71.94M
Diluted Earnings per Share
($0.30) ($0.23) ($0.29) ($0.21) ($0.21) ($0.21) ($0.19) ($0.13) ($0.13) ($0.18) ($0.11)
Weighted Average Diluted Shares Outstanding
34.82M 36.69M 36.81M 36.45M 40.52M 45.90M 46.87M 46.38M 55.50M 55.66M 71.94M
Weighted Average Basic & Diluted Shares Outstanding
36.68M 36.82M 37.41M 45.40M 45.71M 46.63M 48.98M 55.82M 55.82M 55.97M 105.01M

Annual Cash Flow Statements for PDS Biotechnology

This table details how cash moves in and out of PDS Biotechnology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
116 -24 -18 -0.14 12 17 36 8.58 -17 -15 -15
Net Cash From Operating Activities
-22 -32 -41 -1.57 -18 -13 -12 -26 -34 -35 -28
Net Cash From Continuing Operating Activities
-22 -32 -41 -1.64 -18 -13 -12 -26 -34 -35 -28
Net Income / (Loss) Continuing Operations
-28 -39 -51 -3.84 -7.00 -15 -17 -41 -43 -38 -34
Consolidated Net Income / (Loss)
-28 -39 -51 -3.84 -7.00 -15 -17 -41 -43 -38 -34
Depreciation Expense
0.05 0.10 0.18 0.07 0.10 0.02 0.01 0.00 0.02 0.02 0.02
Amortization Expense
0.20 0.17 0.14 - - - 0.00 0.23 0.69 1.20 1.59
Non-Cash Adjustments To Reconcile Net Income
4.82 5.58 6.76 1.05 -6.19 0.49 4.18 10 8.40 7.12 5.51
Changes in Operating Assets and Liabilities, net
1.26 0.78 3.14 1.15 -4.99 1.17 0.25 4.90 0.04 -5.75 -0.38
Net Cash From Investing Activities
-1.31 -0.69 -0.19 0.00 29 0.00 0.00 0.00 0.00 -0.03 0.00
Net Cash From Continuing Investing Activities
-1.31 -0.69 -0.19 0.00 29 0.00 0.00 0.00 0.00 -0.03 0.00
Purchase of Property, Plant & Equipment
-1.31 -0.69 -0.19 - - - - - 0.00 -0.03 0.00
Net Cash From Financing Activities
140 9.08 23 1.50 0.75 30 49 34 16 20 13
Net Cash From Continuing Financing Activities
140 9.08 23 1.50 0.75 30 49 34 16 20 13
Repayment of Debt
-0.53 -1.71 0.00 -0.02 - - 0.00 -0.45 0.00 -3.13 -26
Issuance of Debt
55 11 5.00 - - - 0.00 25 - 0.00 19
Issuance of Common Equity
86 0.00 17 1.28 0.75 30 49 9.86 16 23 19
Other Financing Activities, net
0.00 0.31 0.17 0.23 0.00 0.07 0.34 -0.12 0.25 0.72 -0.06
Cash Interest Paid
0.56 0.79 1.64 0.00 - - 0.00 0.85 3.54 3.56 2.92

Quarterly Cash Flow Statements for PDS Biotechnology

This table details how cash moves in and out of PDS Biotechnology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
10 -8.90 -7.98 -8.06 -1.71 -8.11 -5.67 0.51 -5.05 -16 9.65
Net Cash From Operating Activities
-9.94 -8.86 -8.00 -8.23 -9.03 -9.10 -5.92 -3.70 -4.37 -2.79 -8.22
Net Cash From Continuing Operating Activities
-9.94 -8.86 -8.00 -8.23 -9.03 -9.10 -5.92 -3.70 -4.37 -2.79 -8.22
Net Income / (Loss) Continuing Operations
-11 -8.33 -11 -7.95 -8.49 -9.43 -9.01 -7.56 -7.35 -9.75 -7.62
Consolidated Net Income / (Loss)
-11 -8.33 -11 -7.95 -8.49 -9.43 -9.01 -7.56 -7.35 -9.75 -7.62
Depreciation Expense
0.00 0.02 0.02 0.01 0.02 -0.00 0.01 0.01 0.02 0.02 0.02
Amortization Expense
0.27 0.28 0.31 0.31 0.27 1.11 -0.28 0.48 0.45 0.27 0.55
Non-Cash Adjustments To Reconcile Net Income
1.64 2.05 1.78 1.64 1.46 0.47 1.98 1.61 1.16 3.79 1.95
Changes in Operating Assets and Liabilities, net
-1.25 -2.89 0.63 -2.24 -2.29 -1.24 1.39 1.76 1.36 2.89 -3.11
Net Cash From Financing Activities
20 -0.01 0.02 0.17 7.32 1.00 0.24 4.22 -0.68 -13 18
Net Cash From Continuing Financing Activities
20 -0.01 0.02 0.17 7.32 1.00 0.24 4.22 -0.68 -13 18
Repayment of Debt
0.00 - - - -3.13 -20 -1.00 -1.85 -1.50 -19 -6.03
Issuance of Debt
- - - - 1.01 - 0.00 -0.03 0.00 4.32 3.59
Issuance of Common Equity
19 - -0.07 3.17 9.45 1.46 1.26 7.13 0.83 1.15 17
Other Financing Activities, net
0.52 -0.01 0.08 0.13 -0.01 -0.02 -0.02 -1.03 -0.01 -0.01 3.48
Cash Interest Paid
1.17 1.19 0.36 0.84 0.69 0.89 0.70 0.64 0.56 0.94 0.14

Annual Balance Sheets for PDS Biotechnology

This table presents PDS Biotechnology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
134 111 93 0.16 14 31 67 77 59 45 30
Total Current Assets
131 107 89 0.12 14 30 67 76 59 45 28
Cash & Equivalents
130 106 88 0.10 12 29 65 74 57 42 27
Prepaid Expenses
1.08 0.95 0.99 0.02 2.31 1.50 1.60 2.66 2.49 3.36 1.54
Plant, Property, & Equipment, net
2.77 3.42 3.42 0.03 0.02 0.01 0.00 0.00 0.13 0.14 0.12
Total Noncurrent Assets
0.06 0.14 0.14 0.01 0.00 0.55 0.36 0.53 0.20 0.16 2.12
Noncurrent Note & Lease Receivables
- - - - - - 0.00 0.37 0.20 0.16 0.12
Other Noncurrent Operating Assets
0.06 0.14 0.14 0.01 0.00 0.55 0.36 0.15 - 0.00 2.00
Total Liabilities & Shareholders' Equity
134 111 93 0.16 14 31 67 77 59 45 30
Total Liabilities
12 22 30 2.23 2.79 3.76 3.99 33 33 26 21
Total Current Liabilities
8.59 6.68 13 1.91 2.79 3.27 3.76 9.82 14 17 9.48
Short-Term Debt
2.27 0.00 3.08 - - - - 0.00 4.17 13 5.13
Accounts Payable
2.58 3.47 4.37 1.31 1.20 1.42 1.31 1.22 6.98 1.68 3.57
Accrued Expenses
3.73 3.21 5.42 0.60 1.10 1.74 2.19 8.31 2.42 2.84 0.74
Other Current Liabilities
- - 0.00 0.00 0.50 0.12 0.26 0.29 0.06 0.06 0.04
Total Noncurrent Liabilities
3.03 15 17 0.32 0.00 0.49 0.23 23 20 9.27 12
Long-Term Debt
3.03 15 17 0.03 - - 0.00 23 20 9.20 12
Capital Lease Obligations
- - - - - - 0.00 0.16 0.12 0.06 0.03
Commitments & Contingencies
- - - - - - - - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
122 89 62 -2.07 12 27 63 44 26 19 9.25
Total Preferred & Common Equity
122 89 62 -2.07 12 27 63 44 26 19 9.25
Total Common Equity
122 89 62 -2.07 12 27 63 44 26 19 9.25
Common Stock
185 190 214 20 41 71 124 146 171 201 226
Retained Earnings
-62 -101 -152 -22 -29 -44 -61 -102 -145 -182 -217

Quarterly Balance Sheets for PDS Biotechnology

This table presents PDS Biotechnology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
57 69 60 52 47 40 35 25 8.81 19
Total Current Assets
57 69 60 52 42 34 28 23 7.05 18
Cash & Equivalents
54 67 58 50 40 32 26 22 5.60 15
Prepaid Expenses
2.59 2.05 2.43 2.38 2.49 1.77 1.69 1.23 1.45 3.13
Plant, Property, & Equipment, net
0.14 0.13 0.15 0.15 0.14 0.13 0.13 0.11 0.18 0.17
Total Noncurrent Assets
0.21 0.19 0.18 0.17 4.42 6.70 6.69 1.66 1.59 0.03
Noncurrent Note & Lease Receivables
0.21 0.19 0.18 0.17 0.15 0.14 0.13 0.11 0.04 0.03
Other Noncurrent Operating Assets
0.00 - - - 4.27 6.55 6.55 1.55 1.55 0.00
Total Liabilities & Shareholders' Equity
57 69 60 52 47 40 35 25 8.81 19
Total Liabilities
33 32 30 30 25 25 25 21 12 5.08
Total Current Liabilities
9.15 15 16 18 18 12 13 10 12 5.08
Short-Term Debt
0.00 7.29 10 13 13 5.50 6.00 5.21 4.32 0.00
Accounts Payable
5.37 6.00 3.25 1.30 2.86 4.50 5.18 3.65 6.39 2.99
Accrued Expenses
3.73 1.71 1.95 4.48 2.85 1.48 2.10 1.26 1.63 2.05
Other Current Liabilities
0.05 0.06 0.06 0.06 0.06 0.05 0.04 0.03 0.03 0.03
Total Noncurrent Liabilities
24 17 14 12 6.40 13 12 11 0.01 0.00
Long-Term Debt
23 17 14 12 6.35 13 12 11 0.00 0.00
Capital Lease Obligations
0.14 0.11 0.09 0.08 0.05 0.04 0.03 0.02 0.01 0.00
Commitments & Contingencies
- - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
24 37 31 22 22 16 9.45 3.89 -3.58 13
Total Preferred & Common Equity
24 37 31 22 22 16 9.45 3.89 -3.58 13
Total Common Equity
24 37 31 22 22 16 9.45 3.89 -3.58 13
Common Stock
158 192 194 196 213 216 218 228 230 255
Retained Earnings
-134 -155 -163 -174 -191 -200 -209 -224 -234 -241

Annual Metrics And Ratios for PDS Biotechnology

This table displays calculated financial ratios and metrics derived from PDS Biotechnology's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
28,810,845.00 28,917,419.00 30,859,200.00 31,328,128.00 5,778,850.00 22,261,619.00 28,435,067.00 28,508,688.00 31,107,763.00 - 48,980,307.00
DEI Adjusted Shares Outstanding
1,440,542.00 1,445,871.00 1,542,960.00 1,566,406.00 5,778,850.00 22,261,619.00 28,435,067.00 28,508,688.00 31,107,763.00 - 48,980,307.00
DEI Earnings Per Adjusted Shares Outstanding
-22.52 -26.85 -32.96 -2.45 -1.21 -0.67 -0.60 -1.43 -1.38 - -0.70
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-124.20% -40.11% -31.04% 93.07% -112.46% -95.84% -43.98% -93.34% -2.16% 17.08% 14.74%
EBIT Growth
-125.02% -39.81% -30.98% 92.98% -111.13% -93.54% -43.87% -94.37% -3.29% 15.62% 13.15%
NOPAT Growth
-100.84% -49.11% -31.52% 92.98% -476.89% 29.15% -43.87% -94.37% -3.29% 15.62% 13.15%
Net Income Growth
-130.13% -38.26% -31.01% 92.46% -82.42% -112.15% -13.95% -141.48% -5.11% 12.42% 8.28%
EPS Growth
0.00% 0.00% 0.00% 0.00% -225.22% 38.19% 25.84% -116.67% 2.80% 25.90% 28.16%
Operating Cash Flow Growth
-123.90% -47.98% -26.43% 96.14% -1,051.49% 27.25% 5.04% -105.91% -30.83% -4.14% 20.78%
Free Cash Flow Firm Growth
-159.63% -52.36% -19.36% 83.04% -190.25% 43.99% -59.87% -67.31% -22.64% -3.35% 27.98%
Invested Capital Growth
-10.72% 10.19% -141.47% 59.15% 78.32% -268.51% -18.84% -226.41% -0.01% 86.16% 37.84%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
0.00% -6.15% -11.17% 80.20% -65.03% 11.59% -12.00% -42.59% 16.88% 8.00% 2.80%
EBIT Q/Q Growth
0.00% -5.96% -11.08% 79.89% -62.18% 11.59% -11.98% -42.85% 16.35% 7.74% 2.13%
NOPAT Q/Q Growth
0.00% -5.52% -11.08% 79.90% -26.06% 11.59% -11.98% -42.85% 16.35% 7.74% 2.13%
Net Income Q/Q Growth
0.00% -4.18% -9.44% 75.90% -50.82% 1.01% -15.68% -45.72% 16.10% 7.26% 1.12%
EPS Q/Q Growth
0.00% 0.00% 0.00% 75.90% -63.64% -12.66% -29.41% -38.84% 17.75% 11.97% 9.76%
Operating Cash Flow Q/Q Growth
-21.83% 2.24% -8.52% 85.04% -40.42% 6.34% 1.01% -13.35% -2.84% 0.63% 14.04%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% -7.82% 38.46% -4.55% 21.49% -9.29% -16.86% 3.08% -1.65% 16.56%
Invested Capital Q/Q Growth
0.00% -372.60% -126.22% 63.30% 74.56% 11.04% -7.69% -417.08% -6.70% 70.77% -148.46%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
96.21% 95.46% 95.16% 100.00% 94.83% 100.00% 78.93% 97.15% 96.83% 97.74% 96.72%
Interest Burden Percent
102.85% 102.50% 102.85% 105.19% 95.85% 99.63% 99.98% 100.92% 103.03% 105.94% 113.07%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-42.73% -36.67% -67.08% -12.72% -145.33% -76.48% -37.46% -76.21% -122.46% -166.65% -244.16%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-30.77% -36.67% -67.08% -12.72% -145.33% -76.48% -37.46% -76.21% -122.46% -166.65% -244.16%
Return on Equity Simple (ROE_SIMPLE)
-22.93% -43.48% -81.54% 185.68% -59.83% -54.73% -26.77% -92.85% -164.33% -197.90% 0.00%
Net Operating Profit after Tax (NOPAT)
-19 -28 -36 -2.55 -15 -10 -15 -29 -30 -25 -22
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-14.01% -10.32% -18.21% -3.79% 126.28% -21.54% -4.06% -20.17% -30.72% -46.26% -83.47%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -60.35% -62.36% -84.47%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-28 -40 -52 -3.65 -7.70 -15 -21 -42 -43 -36 -32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-28 -39 -52 -3.58 -7.60 -15 -21 -41 -42 -35 -30
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.94 4.05 4.64 0.00 1.31 1.76 3.64 8.55 5.92 3.21 4.08
Price to Tangible Book Value (P/TBV)
2.94 4.05 4.64 0.00 1.31 1.76 3.64 8.55 5.92 3.21 4.08
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.04 0.17 0.33 -0.01 0.00 0.00 0.00 0.53 0.91 1.15 1.83
Long-Term Debt to Equity
0.02 0.17 0.28 -0.01 0.00 0.00 0.00 0.53 0.75 0.49 1.27
Financial Leverage
-1.04 -1.02 -1.05 -1.12 -1.27 -1.06 -1.04 -1.08 -1.19 -1.17 -1.05
Leverage Ratio
1.15 1.16 1.34 1.54 1.52 1.17 1.09 1.35 1.94 2.32 2.68
Compound Leverage Factor
1.18 1.19 1.38 1.62 1.46 1.16 1.09 1.36 2.00 2.46 3.04
Debt to Total Capital
4.15% 14.35% 24.70% -1.47% 0.00% 0.00% 0.00% 34.51% 47.66% 53.39% 64.61%
Short-Term Debt to Total Capital
1.78% 0.00% 3.71% 0.00% 0.00% 0.00% 0.00% 0.00% 8.35% 30.66% 19.63%
Long-Term Debt to Total Capital
2.37% 14.35% 20.99% -1.47% 0.00% 0.00% 0.00% 34.51% 39.32% 22.73% 44.98%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
95.85% 85.65% 75.30% 101.47% 100.00% 100.00% 100.00% 65.49% 52.34% 46.61% 35.39%
Debt to EBITDA
-0.19 -0.38 -0.40 -0.01 0.00 0.00 0.00 -0.56 -0.56 -0.62 -0.56
Net Debt to EBITDA
4.44 2.32 1.31 0.02 0.00 0.00 0.00 1.22 0.77 0.57 0.33
Long-Term Debt to EBITDA
-0.11 -0.38 -0.34 -0.01 0.00 0.00 0.00 -0.56 -0.46 -0.26 -0.39
Debt to NOPAT
-0.29 -0.54 -0.56 -0.01 0.00 0.00 0.00 -0.79 -0.79 -0.86 -0.76
Net Debt to NOPAT
6.73 3.31 1.86 0.03 0.00 0.00 0.00 1.74 1.09 0.78 0.44
Long-Term Debt to NOPAT
-0.16 -0.54 -0.48 -0.01 0.00 0.00 0.00 -0.79 -0.65 -0.36 -0.53
Altman Z-Score
18.35 8.66 2.57 -270.33 -0.29 5.08 33.47 4.25 -2.09 -6.14 -11.55
Noncontrolling Interest Sharing Ratio
27.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
15.28 16.06 6.92 0.06 5.18 9.28 17.80 7.79 4.33 2.64 2.98
Quick Ratio
15.16 15.92 6.84 0.05 4.35 8.82 17.37 7.52 4.15 2.44 2.82
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-18 -28 -33 -5.65 -16 -9.19 -15 -25 -30 -31 -22
Operating Cash Flow to CapEx
-1,666.76% -4,687.41% -21,564.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -120,793.87% 0.00%
Free Cash Flow to Firm to Interest Expense
-22.43 -23.18 -15.28 -29.83 -488.69 0.00 0.00 -18.66 -7.16 -6.66 -4.20
Operating Cash Flow to Interest Expense
-26.64 -26.74 -18.67 -8.29 -538.56 0.00 0.00 -19.53 -8.00 -7.50 -5.20
Operating Cash Flow Less CapEx to Interest Expense
-28.24 -27.31 -18.75 -8.29 -530.36 0.00 0.00 -19.53 -8.00 -7.50 -5.20
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-2.42 -2.17 -5.24 -2.14 -0.46 -1.71 -2.03 -6.63 -6.63 -0.92 -0.57
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-0.23 0.25 -3.07 3.10 1.68 -1.25 -0.32 -4.60 -0.00 5.72 0.35
Enterprise Value (EV)
235 270 222 9.98 3.15 19 165 326 122 41 28
Market Capitalization
360 361 289 10 15 48 230 376 155 61 38
Book Value per Share
$4.25 $3.09 $2.02 ($0.07) $2.02 $1.22 $2.22 $1.54 $0.84 $0.51 $0.19
Tangible Book Value per Share
$4.25 $3.09 $2.02 ($0.07) $2.02 $1.22 $2.22 $1.54 $0.84 $0.51 $0.19
Total Capital
128 104 83 -2.04 12 27 63 67 50 41 26
Total Debt
5.30 15 20 0.03 0.00 0.00 0.00 23 24 22 17
Total Long-Term Debt
3.03 15 17 0.03 0.00 0.00 0.00 23 20 9.27 12
Net Debt
-125 -91 -68 -0.07 -12 -29 -65 -51 -33 -20 -9.82
Capital Expenditures (CapEx)
1.31 0.69 0.19 0.00 -0.28 0.00 0.00 0.00 0.00 0.03 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-5.24 -5.73 -8.80 -1.89 -0.49 -1.77 -2.16 -7.16 -6.97 -1.22 -2.81
Debt-free Net Working Capital (DFNWC)
125 101 79 -1.79 12 27 63 67 50 40 24
Net Working Capital (NWC)
123 101 76 -1.79 12 27 63 67 45 28 19
Net Nonoperating Expense (NNE)
9.53 11 14 1.28 -7.73 4.42 1.91 12 13 12 12
Net Nonoperating Obligations (NNO)
-125 -91 -68 -0.07 -12 -29 -65 -51 -33 -20 -9.82
Total Depreciation and Amortization (D&A)
0.25 0.27 0.32 0.07 0.10 0.02 0.01 0.23 0.71 1.22 1.61
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $0.00 $0.00 $1.44 ($0.89) ($0.66) ($1.43) ($1.39) ($1.03) ($0.74)
Adjusted Weighted Average Basic Shares Outstanding
1.44M 1.45M 1.54M 1.58M 15.29M 22.26M 25.60M 28.60M 30.95M 36.45M 46.38M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $1.44 ($0.89) ($0.66) ($1.43) ($1.39) ($1.03) ($0.74)
Adjusted Weighted Average Diluted Shares Outstanding
1.44M 1.45M 1.54M 1.58M 15.29M 22.26M 25.60M 28.60M 30.95M 36.45M 46.38M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $1.44 ($0.89) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
404.40K 1.44M 1.52M 1.56M 4.87M 16.75M 28.45M 30.72M 36.68M 45.40M 55.82M
Normalized Net Operating Profit after Tax (NOPAT)
-19 -28 -36 -2.55 -13 -10 -15 -29 -30 -25 -22
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-34.76 -32.96 -23.84 -19.26 -229.45 0.00 0.00 -31.65 -10.23 -7.77 -5.91
NOPAT to Interest Expense
-22.72 -22.98 -16.69 -13.48 -438.76 0.00 0.00 -22.16 -7.16 -5.44 -4.14
EBIT Less CapEx to Interest Expense
-36.36 -33.53 -23.92 -19.26 -221.25 0.00 0.00 -31.65 -10.23 -7.78 -5.91
NOPAT Less CapEx to Interest Expense
-24.32 -23.55 -16.77 -13.48 -430.56 0.00 0.00 -22.16 -7.16 -5.45 -4.14
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-5.00% -1.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for PDS Biotechnology

This table displays calculated financial ratios and metrics derived from PDS Biotechnology's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
36,679,275.00 36,679,275.00 36,819,810.00 - 45,395,851.00 45,710,000.00 46,633,362.00 48,980,307.00 55,815,653.00 55,815,653.00 55,971,338.00
DEI Adjusted Shares Outstanding
36,679,275.00 36,679,275.00 36,819,810.00 - 45,395,851.00 45,710,000.00 46,633,362.00 48,980,307.00 55,815,653.00 55,815,653.00 55,971,338.00
DEI Earnings Per Adjusted Shares Outstanding
-0.29 -0.23 -0.29 - -0.19 -0.21 -0.19 -0.15 -0.13 -0.17 -0.14
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-5.78% 33.37% 5.00% 30.24% 10.23% 22.23% 14.66% 12.24% 31.31% 4.28% 36.75%
EBIT Growth
-7.17% 31.60% 3.24% 29.27% 9.82% 12.22% 20.03% 9.32% 28.39% 14.78% 27.57%
NOPAT Growth
-7.17% 31.60% 3.24% 29.27% 9.82% 12.22% 20.03% 9.32% 28.39% 14.78% 27.57%
Net Income Growth
-9.77% 27.80% 1.13% 27.03% 19.94% -13.28% 16.01% 4.90% 13.43% -3.35% 15.41%
EPS Growth
6.25% 37.84% 17.14% 40.00% 30.00% 8.70% 34.48% 38.10% 38.10% 14.29% 42.11%
Operating Cash Flow Growth
24.65% -83.99% -11.48% 2.63% 9.12% -2.75% 26.05% 55.04% 51.60% 69.32% -39.01%
Free Cash Flow Firm Growth
70.78% -44.79% -319.96% -49.20% -412.39% -25.37% 1.81% 53.81% 89.72% 127.56% 88.01%
Invested Capital Growth
-513.44% 47.07% 49.48% 86.16% 123.79% 203.01% 137.50% 37.84% -250.84% -288.40% -248.50%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
2.77% 14.73% -17.70% 28.37% -25.12% 26.13% -29.16% 26.48% 2.07% -2.62% 14.20%
EBIT Q/Q Growth
2.97% 14.00% -17.21% 27.69% -23.71% 16.28% -6.78% 18.00% 2.30% 0.37% 9.25%
NOPAT Q/Q Growth
2.97% 14.00% -17.21% 27.69% -23.71% 16.28% -6.78% 18.00% 2.30% 0.37% 9.25%
Net Income Q/Q Growth
2.70% 21.46% -28.80% 25.86% -6.75% -11.13% 4.50% 16.06% 2.83% -32.68% 21.84%
EPS Q/Q Growth
14.29% 23.33% -26.09% 27.59% 0.00% 0.00% 9.52% 31.58% 0.00% -38.46% 38.89%
Operating Cash Flow Q/Q Growth
-17.51% 10.87% 9.69% -2.93% -9.69% -0.76% 35.00% 37.41% -18.07% 36.12% -194.49%
Free Cash Flow Firm Q/Q Growth
65.01% -225.61% -22.94% -6.53% -20.16% 20.33% 3.72% 49.89% 73.25% 313.57% -141.88%
Invested Capital Q/Q Growth
18.60% 53.78% -25.84% 70.77% 239.91% 100.16% -54.20% -148.46% -239.50% -150.00% 63.90%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 90.55% 100.00% 100.00% 87.89% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
105.01% 105.90% 105.38% 108.04% 106.07% 123.75% 110.68% 113.31% 112.70% 150.08% 129.25%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-112.25% -128.40% -174.49% -166.65% -119.22% -156.16% -221.81% -244.16% -254.09% -543.97% -281.35%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% -2,445.66% -1,130.05% -2,282.38% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-112.25% -128.40% -174.49% -166.65% -119.22% -156.16% -221.81% -244.16% -254.09% -543.97% -281.35%
Return on Equity Simple (ROE_SIMPLE)
-118.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-7.07 -6.08 -7.13 -5.15 -6.37 -5.34 -5.70 -4.67 -4.56 -4.55 -4.13
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-8.37% -6.37% -12.90% -10.63% -6.64% -17.51% -19.82% -19.44% -20.70% -71.01% -29.71%
Return On Investment Capital (ROIC_SIMPLE)
-11.54% -11.01% -15.29% -12.64% -15.45% -15.49% -20.81% -17.87% -23.14% -604.56% -30.58%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-10 -8.68 -10 -7.36 -9.11 -7.62 -8.14 -6.67 -6.52 -6.50 -5.90
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-9.82 -8.38 -9.86 -7.05 -8.82 -6.51 -8.41 -6.19 -6.06 -6.22 -5.33
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
3.91 3.48 6.39 3.21 2.42 3.81 4.98 4.08 8.67 0.00 3.11
Price to Tangible Book Value (P/TBV)
3.91 3.48 6.39 3.21 2.42 3.81 4.98 4.08 8.67 0.00 3.11
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 25.65 18.44 32.97 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.65 0.79 1.12 1.15 0.85 1.16 1.90 1.83 4.07 -1.21 0.00
Long-Term Debt to Equity
0.45 0.45 0.55 0.49 0.29 0.81 1.26 1.27 2.73 0.00 0.00
Financial Leverage
-1.08 -1.11 -1.20 -1.17 -1.07 -1.00 -1.06 -1.05 -1.02 -1.18 -1.02
Leverage Ratio
1.76 1.96 2.36 2.32 1.95 2.15 2.77 2.68 2.73 3.98 2.32
Compound Leverage Factor
1.85 2.08 2.49 2.51 2.07 2.67 3.07 3.04 3.08 5.97 3.00
Debt to Total Capital
39.28% 44.03% 52.80% 53.39% 45.81% 53.67% 65.47% 64.61% 80.26% 575.88% 0.01%
Short-Term Debt to Total Capital
11.91% 18.86% 26.82% 30.66% 30.29% 15.97% 21.92% 19.63% 26.40% 574.62% 0.00%
Long-Term Debt to Total Capital
27.37% 25.17% 25.98% 22.73% 15.51% 37.70% 43.55% 44.98% 53.86% 1.26% 0.01%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
60.72% 55.97% 47.20% 46.61% 54.19% 46.33% 34.53% 35.39% 19.74% -475.88% 99.99%
Debt to EBITDA
-0.56 -0.63 -0.64 -0.62 -0.55 -0.57 -0.58 -0.56 -0.58 -0.16 0.00
Net Debt to EBITDA
0.99 0.86 0.66 0.57 0.62 0.42 0.27 0.33 0.21 0.05 0.64
Long-Term Debt to EBITDA
-0.39 -0.36 -0.32 -0.26 -0.19 -0.40 -0.39 -0.39 -0.39 0.00 0.00
Debt to NOPAT
-0.79 -0.87 -0.89 -0.86 -0.76 -0.77 -0.79 -0.76 -0.78 -0.22 0.00
Net Debt to NOPAT
1.39 1.20 0.91 0.78 0.85 0.56 0.37 0.44 0.29 0.06 0.85
Long-Term Debt to NOPAT
-0.55 -0.50 -0.44 -0.36 -0.26 -0.54 -0.53 -0.53 -0.52 0.00 0.00
Altman Z-Score
0.04 -1.19 -1.74 -4.03 -4.38 -5.40 -7.58 -8.86 -11.99 -37.93 -13.41
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.56 3.84 2.84 2.64 2.33 2.92 2.09 2.98 2.26 0.57 3.62
Quick Ratio
4.42 3.68 2.71 2.44 2.19 2.76 1.97 2.82 2.13 0.45 3.00
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-2.55 -8.30 -10 -11 -13 -10 -10 -5.02 -1.34 2.87 -1.20
Operating Cash Flow to CapEx
0.00% 0.00% -799,968,700.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
-2.17 -6.99 -8.40 -9.92 -14.03 -4.85 -8.71 -4.51 -1.32 0.85 -0.68
Operating Cash Flow to Interest Expense
-8.46 -7.46 -6.59 -7.52 -9.70 -4.24 -5.14 -3.33 -4.31 -0.83 -4.66
Operating Cash Flow Less CapEx to Interest Expense
-8.46 -7.46 -6.59 -7.52 -9.70 -4.24 -5.14 -3.33 -4.31 -0.83 -4.66
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-5.40 -2.50 -3.14 -0.92 1.28 2.57 1.18 -0.57 -1.94 -4.84 -1.75
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-4.52 2.22 3.08 5.72 6.68 5.07 4.32 0.35 -3.22 -7.42 -2.93
Enterprise Value (EV)
103 74 116 41 33 47 39 28 28 48 27
Market Capitalization
145 107 141 61 54 61 47 38 34 49 42
Book Value per Share
$1.01 $0.84 $0.60 $0.51 $0.49 $0.35 $0.20 $0.19 $0.07 ($0.06) $0.24
Tangible Book Value per Share
$1.01 $0.84 $0.60 $0.51 $0.49 $0.35 $0.20 $0.19 $0.07 ($0.06) $0.24
Total Capital
61 55 47 41 41 34 27 26 20 0.75 13
Total Debt
24 24 25 22 19 18 18 17 16 4.33 0.00
Total Long-Term Debt
17 14 12 9.27 6.40 13 12 12 11 0.01 0.00
Net Debt
-43 -33 -25 -20 -21 -13 -8.28 -9.82 -5.83 -1.26 -15
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-5.72 -2.83 -3.46 -1.22 -3.28 -4.26 -5.64 -2.81 -3.71 -6.61 -1.95
Debt-free Net Working Capital (DFNWC)
61 55 46 40 37 28 21 24 18 -1.01 13
Net Working Capital (NWC)
54 44 34 28 24 22 15 19 13 -5.33 13
Net Nonoperating Expense (NNE)
3.54 2.25 3.60 2.80 2.11 4.10 3.31 2.89 2.78 5.20 3.49
Net Nonoperating Obligations (NNO)
-43 -33 -25 -20 -21 -13 -8.28 -9.82 -5.83 -1.26 -15
Total Depreciation and Amortization (D&A)
0.27 0.31 0.32 0.31 0.29 1.11 -0.27 0.49 0.46 0.28 0.56
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.30) ($0.23) ($0.29) ($0.21) ($0.21) ($0.21) ($0.19) ($0.13) ($0.13) ($0.18) ($0.11)
Adjusted Weighted Average Basic Shares Outstanding
34.82M 36.69M 36.81M 36.45M 40.52M 45.90M 46.87M 46.38M 55.50M 55.66M 71.94M
Adjusted Diluted Earnings per Share
($0.30) ($0.23) ($0.29) ($0.21) ($0.21) ($0.21) ($0.19) ($0.13) ($0.13) ($0.18) ($0.11)
Adjusted Weighted Average Diluted Shares Outstanding
34.82M 36.69M 36.81M 36.45M 40.52M 45.90M 46.87M 46.38M 55.50M 55.66M 71.94M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
36.68M 36.82M 37.41M 45.40M 45.71M 46.63M 48.98M 55.82M 55.82M 55.97M 105.01M
Normalized Net Operating Profit after Tax (NOPAT)
-7.07 -6.08 -7.13 -5.15 -6.37 -5.34 -5.70 -4.67 -4.56 -4.55 -4.13
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-8.60 -7.31 -8.38 -6.72 -9.78 -3.55 -7.08 -6.00 -6.43 -1.92 -3.34
NOPAT to Interest Expense
-6.02 -5.12 -5.87 -4.70 -6.85 -2.49 -4.95 -4.20 -4.50 -1.35 -2.34
EBIT Less CapEx to Interest Expense
-8.60 -7.31 -8.38 -6.72 -9.78 -3.55 -7.08 -6.00 -6.43 -1.92 -3.34
NOPAT Less CapEx to Interest Expense
-6.02 -5.12 -5.87 -4.70 -6.85 -2.49 -4.95 -4.20 -4.50 -1.35 -2.34
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

PDS Biotechnology (NASDAQ:PDSB) remains a development-stage biotechnology company with no reported revenue across the periods provided. Its financial profile continues to be driven by research spending, clinical-development costs, financing activity and cash consumption rather than commercial operations.

The company has made some progress reducing expenses and debt, but its liquidity position has deteriorated sharply. Cash and equivalents declined from $66.6 million in Q1 2024 to $5.6 million in Q2 2026, while shareholders’ equity turned negative. This leaves PDSB dependent on additional financing, partnerships or revenue-generating milestones to fund operations.

  • Operating expenses have generally declined. Total operating expenses fell from $10.5 million in Q3 2023 and $10.1 million in Q1 2024 to $6.5 million in Q2 2026. Research and development expense also declined to $3.3 million in Q2 2026 from $7.5 million in Q4 2023.
  • Debt has been reduced substantially. Total debt, including short- and long-term borrowings, was approximately $23.4 million in Q3 2023 and $25.9 million in Q2 2024, compared with about $4.3 million of short-term debt and no long-term debt at the end of Q2 2026.
  • Quarterly net losses improved from the earlier periods. The Q2 2026 net loss was $9.8 million, compared with losses of $10.9 million in Q3 2023 and $10.6 million in Q1 2024. The Q1 2026 loss was lower at $7.3 million, although the improvement was not sustained in Q2.
  • Financing has provided recurring access to capital. PDSB raised approximately $9.5 million through common equity in Q1 2024, $7.1 million in Q4 2025, and additional equity in subsequent quarters. These financings have helped support operations and debt repayment.
  • Cash flow remains negative but is influenced by non-cash adjustments and working capital changes. Operating cash flow was negative in every reported quarter, ranging from negative $3.7 million to negative $9.9 million. In Q2 2026, non-cash adjustments and working-capital changes reduced the cash impact of the $9.8 million net loss, but operating cash flow was still negative $2.8 million.
  • There is no meaningful revenue base yet. Reported revenue was zero in the available income statements, so future financial performance will depend heavily on clinical progress, licensing arrangements, partnerships or eventual product commercialization.
  • Liquidity has deteriorated rapidly. Cash fell from $39.9 million in Q1 2025 and $21.7 million in Q1 2026 to just $5.6 million in Q2 2026. The company also reported a $16.1 million quarterly decline in cash during Q2, largely reflecting debt repayment and operating cash use.
  • PDSB reported negative shareholders’ equity in Q2 2026. Total liabilities of $12.4 million exceeded total assets of $8.8 million, producing negative equity of approximately $3.6 million. This represents a significant deterioration from positive equity of $22.4 million in Q1 2024.
  • The company continues to consume cash from operations. Operating cash flow was negative $9.0 million in Q1 2024, negative $9.1 million in Q2 2025, negative $3.7 million in Q4 2025 and negative $4.4 million in Q1 2026. Without new funding or a material reduction in spending, the remaining cash balance appears limited relative to ongoing needs.
  • Share dilution has been substantial. Weighted-average basic shares increased from approximately 30.9 million in Q3 2023 to 55.7 million in Q2 2026. Repeated equity issuance has supported the balance sheet but reduces each existing shareholder’s ownership percentage and increases the financing burden.

Overall, the trend is financially mixed but increasingly pressured. Lower operating expenses and reduced debt are constructive developments, yet they have been outweighed by the absence of revenue, persistent operating losses, rapid cash depletion, negative equity and significant share dilution. Retail investors should closely monitor the company’s financing plans, cash runway, clinical milestones and any potential partnership or commercialization proceeds.

11/21/26 05:15 AM ETAI Generated. May Contain Errors.

PDS Biotechnology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, PDS Biotechnology's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

PDS Biotechnology's net income appears to be on a downward trend, with a most recent value of -$34.50 million in 2025, falling from -$28.08 million in 2015. The previous period was -$37.61 million in 2024. View PDS Biotechnology's forecast to see where analysts expect PDS Biotechnology to go next.

PDS Biotechnology's total operating income in 2025 was -$31.54 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $31.54 million

Over the last 10 years, PDS Biotechnology's total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

In the past 12 quarters, PDS Biotechnology's cash and equivalents has ranged from $5.60 million in Q2 2026 to $66.63 million in Q1 2024, and is currently $15.25 million as of their latest financial filing in Q3 2026.

PDS Biotechnology had total debt of $16.89 million at the end of 2025, a 22.4% decrease from 2024, and a 218.9% increase since 2015.

Over the last 10 years, PDS Biotechnology's book value per share changed from 4.25 in 2015 to 0.19 in 2025, a change of -95.6%.



Financial statements for NASDAQ:PDSB last updated on 11/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners